Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Pharmacologic and Pharmacodynamic Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers

NCT01209195 is registered in ClinicalTrials.gov with Merrimack Pharmaceuticals as lead sponsor.

NCT NCT01209195
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01209195 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Pharmacologic and Pharmacodynamic Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
Lead sponsor
Merrimack Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2010
Completion date
July 31, 2014
Enrollment
41 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced/metastatic her2 non overexpressing breast cancer, locally advanced/metastatic or recurrent ovarian cancer, fallopian tube cancer,, primary peritoneal cancer or endometrial cancer